Correlation of Genetic Susceptibility Genes to Inflammatory Bowel Disease in Chinese Han Population (CGSGIBDCHP)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05071742 |
Recruitment Status :
Recruiting
First Posted : October 8, 2021
Last Update Posted : November 16, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Gene Abnormality Inflammatory Bowel Disease Chinese | Genetic: 2ml peripheral venous blood was collected to detect genetic genes |
Study Type : | Observational |
Estimated Enrollment : | 500 participants |
Observational Model: | Case-Control |
Time Perspective: | Cross-Sectional |
Official Title: | Correlation of Genetic Susceptibility Genes to Inflammatory Bowel Disease in Chinese Han Population |
Estimated Study Start Date : | November 25, 2021 |
Estimated Primary Completion Date : | December 31, 2023 |
Estimated Study Completion Date : | December 31, 2024 |
Group/Cohort | Intervention/treatment |
---|---|
IBD group
According to the consensus opinions on diagnosis and Treatment of Inflammatory Bowel Disease (Beijing, 2018) formulated by Chinese Society of Gastroenterology, Chinese Medical Association The diagnosis of IBD was confirmed by clinical, laboratory, radiographic, digestive endoscopy and histopathological examination.
|
Genetic: 2ml peripheral venous blood was collected to detect genetic genes
Extraction of whole genome DNA: 2 mL of peripheral fasting venous blood was extracted, and edTA disodium was anticoagulant.The whole-genome DNA was extracted strictly in accordance with the instructions of the blood genomic DNA extraction kit (Beijing Tiagen Biochemical Technology Co., LTD., China), and the DNA concentration and purity were detected by nanodrop-1000 spectrophotometer (Thermo, USA). The DNA was diluted to 10 ng/μL and stored in a refrigerator at -80℃ for future use. (2) Primer design and synthesis: (3) Gene polymorphism detection 4) Resin purification 5) Spot chip and mass spectrometry detection Other Name: DNA is extracted and genetic testing is performed |
control group
During the same period, healthy subjects were collected from the physical examination center of our hospital as subjects of the normal control group. Infectious diarrhea, ischemic bowel disease, radiation enteritis, gastrointestinal tumor, diabetes, systemic lupus erythematosus, rheumatoid arthritis and autoimmune thyroiditis were excluded from all clinical examinations before inclusion.
|
Genetic: 2ml peripheral venous blood was collected to detect genetic genes
Extraction of whole genome DNA: 2 mL of peripheral fasting venous blood was extracted, and edTA disodium was anticoagulant.The whole-genome DNA was extracted strictly in accordance with the instructions of the blood genomic DNA extraction kit (Beijing Tiagen Biochemical Technology Co., LTD., China), and the DNA concentration and purity were detected by nanodrop-1000 spectrophotometer (Thermo, USA). The DNA was diluted to 10 ng/μL and stored in a refrigerator at -80℃ for future use. (2) Primer design and synthesis: (3) Gene polymorphism detection 4) Resin purification 5) Spot chip and mass spectrometry detection Other Name: DNA is extracted and genetic testing is performed |
- Correlation of genetic susceptibility genes to inflammatory bowel disease in Chinese Han population [ Time Frame: 2021-2024 ]The difference in mutation frequency of different gene loci between IBD patients and control group was compared.
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Gender Based Eligibility: | Yes |
Gender Eligibility Description: | Adults who have not undergone acquired sex reassignment surgery can be included |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Confirmed IBD patients were collected from the Department of Gastroenterology, The Second Affiliated Hospital of Wenzhou Medical University.According to the consensus of "Diagnosis and treatment of inflammatory bowel disease" formulated by Chinese Society of Gastroenterology, the diagnosis of IBD was established by clinical, laboratory, radiographic, digestive endoscopy and histopathological examination.During the same period, 476 healthy subjects were collected from the physical examination center of our hospital as the normal control group
Exclusion Criteria:
- Active infection, malignant tumor, congestive heart failure, demyelination of nervous system, allergy to rat derived protein components, etc All subjects were excluded from infectious diarrhea, ischemic enteropathy, radiation enteritis, gastrointestinal tumor, diabetes, systemic lupus erythematosus, rheumatoid arthritis and autoimmune thyroiditis by clinical examination before inclusion.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05071742
Contact: Yi Jiang, PHD | +86 13676715542 | wzjiangyi@yeah.net |
China, Zhejiang | |
The Second Affiliated Hospital of Wenzhou Medical University | Recruiting |
Wenzhou, Zhejiang, China, 325000 | |
Contact: Xiaoxiao Shao, PHD +8615967465468 494311941@qq.com |
Study Director: | Ting Li, PHD | Second Affiliated Hospital of Wenzhou Medical University |
Responsible Party: | Xiao xiao Shao, attending doctor, Second Affiliated Hospital of Wenzhou Medical University |
ClinicalTrials.gov Identifier: | NCT05071742 |
Other Study ID Numbers: |
SAHoWMU-CR2021-01-206 |
First Posted: | October 8, 2021 Key Record Dates |
Last Update Posted: | November 16, 2021 |
Last Verified: | November 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
IBD;gene;Chinese Han population |
Intestinal Diseases Inflammatory Bowel Diseases Genetic Predisposition to Disease Gastrointestinal Diseases Digestive System Diseases |
Gastroenteritis Disease Susceptibility Disease Attributes Pathologic Processes |